Ilumetri

Tildrakizumab, the active ingredient in Ilumetri, is a selective humanized IgG1κ monoclonal antibody classified as an interleukin‑23 (IL‑23) inhibitor, presented as a 100 mg subcutaneous injection for subcutaneous use. It is indicated for the treatment of moderate‑to‑severe plaque psoriasis in adult patients.

GNH USA supplies Ilumetri as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures product integrity through cold‑chain logistics and adheres to stringent quality standards across global markets.

Ilumetri (tildrakizumab) targets the interleukin‑23 pathway and is used in the management of psoriasis.

- Plaque psoriasis (moderate‑to‑severe): reduces skin lesions and improves quality of life. - Chronic plaque psoriasis: lowers PASI scores and achieves sustained skin clearance. - Adult psoriasis patients: provides long‑term disease control when topical therapies are insufficient.

Ilumetri may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects: - Injection site pain or erythema. - Upper respiratory tract infection. - Headache. - Nasopharyngitis. - Fungal skin infection. - Mild fatigue.

Serious or Rare Side Effects: - Severe hypersensitivity reactions, including anaphylaxis. - Opportunistic infections such as tuberculosis reactivation. - Malignancies, including lymphoma and skin cancer. - Neutropenia or other hematologic abnormalities. - Cardiovascular events (rare).

Before initiating Ilumetri, clinicians should evaluate patient history and monitor for potential risks.

- Screen for active infections: assess and treat before starting therapy. - Update vaccination status: administer required vaccines prior to treatment. - Monitor for signs of infection: report fever, chills, or persistent cough. - Assess for hypersensitivity: discontinue if severe allergic reaction occurs. - Pregnancy and lactation: use only if potential benefit justifies potential risk (category unknown). - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ilumetri has a limited interaction profile, but certain agents require caution.

Major Interactions (Avoid): - Live vaccines: contraindicated during therapy due to immunosuppression. - Concurrent use of other biologics targeting the same pathway.

Moderate Interactions (Monitor Closely): - Systemic corticosteroids: may increase infection risk, monitor closely. - Other immunosuppressants (e.g., methotrexate): assess cumulative immunosuppression. - Cytochrome P450 substrates: minimal interaction, but monitor drug levels if clinically relevant.